Core Viewpoint - Shanghai Junshi Biosciences has received approval for clinical trials of JT118, a vaccine aimed at preventing monkeypox virus infection, marking a significant step in the company's vaccine development efforts [1][2]. Group 1: Drug Information - The drug JT118 is a "two-in-one" recombinant protein vaccine composed of monkeypox virus antigens A35 and M1, designed primarily for the prevention of monkeypox virus infection [2]. - Preclinical studies have shown that JT118 can generate high levels of neutralizing antibodies and activate cellular immunity in animal models, demonstrating significant protective effects against monkeypox virus infections [2]. Group 2: Regulatory Approval - The clinical trial application for JT118 was approved by the National Medical Products Administration, allowing the company to proceed with the necessary clinical trials [1]. - The approval was based on compliance with the relevant requirements of the Drug Administration Law and the Vaccine Administration Law of the People's Republic of China [1]. Group 3: Collaboration and Market Context - The company has established a collaboration with Beihang University to jointly develop the monkeypox recombinant protein vaccine [2]. - As of the date of this announcement, there are no approved vaccines for the prevention of monkeypox virus infection in China, indicating a potential market opportunity for JT118 [2].

Core Viewpoint - Junshi Bioscience announced that its subsidiary, Shanghai Juntao Biopharmaceutical Technology Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of the JT118 injection, a recombinant protein vaccine aimed at preventing monkeypox virus infection [1] Group 1 - The clinical trial application for JT118 has been approved, indicating progress in the development of this vaccine [1] - JT118 is a "two-in-one" recombinant protein vaccine composed of monkeypox virus antigens A35 and M1, highlighting its innovative approach to vaccine development [1]

Market Overview - The Hang Seng Index is constrained by the March high of 24,874 points, with expectations of new financial policies from mainland China to stabilize the market, including reserve requirement ratio cuts and interest rate reductions [2] - The recent US-China trade negotiations have led to a temporary reduction in tariffs, with US tariffs on Chinese imports dropping from 145% to 30%, and Chinese tariffs on US goods decreasing from 125% to 10% for a 90-day period [2][3] - The Hang Seng Index's valuation has returned to reasonable levels, requiring significant positive developments in trade agreements and corporate earnings improvements to maintain upward momentum [2] Sector Focus - The report highlights a positive outlook for sectors such as financial stocks, automotive parts, and gold mining stocks, driven by recent developments in trade agreements and geopolitical factors [7][8] - The automotive sector in mainland China saw a year-on-year sales increase of 11.2% in May, with new energy vehicle sales rising by 36.9% [9] Company News - Horizon Robotics plans to raise approximately HKD 47 billion through a share placement at a discount of nearly 7% [10] - Kintor Pharmaceutical is preparing for an IPO in Hong Kong, aiming to raise around USD 100 million [10] - Pop Mart has expanded its production capacity but still faces supply shortages due to high demand for its products [11] - JD Logistics is expanding its operations in Saudi Arabia, having recruited over a thousand staff for its logistics services [10] - Alibaba is focusing on re-establishing its leadership in the technology sector, emphasizing AI and cloud infrastructure as key strategic pillars [10] Economic Indicators - The US Consumer Price Index (CPI) for May showed a year-on-year increase of 2.4%, with core CPI rising by 0.1% month-on-month, indicating that tariffs have not yet significantly impacted overall inflation levels [8] - The Federal Reserve is expected to maintain interest rates, with projections indicating two rate cuts totaling 0.5% for the year [4][8]